These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 2183534)

  • 1. Lack of antibody formation during long-term subcutaneous treatment with the somatostatin analogue octreotide in acromegaly.
    van Liessum PA; Swinkels LM; Pieters GF; Ross AA; Smals AG; Benraad TJ; Kloppenborg PW
    Acta Endocrinol (Copenh); 1990 Mar; 122(3):309-12. PubMed ID: 2183534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of antibodies against octreotide in two patients with acromegaly.
    Orskov H; Christensen SE; Weeke J; Kaal A; Harris AG
    Clin Endocrinol (Oxf); 1991 May; 34(5):395-8. PubMed ID: 2060149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Occurrence and effects of octreotide antibodies during nasal, subcutaneous and slow release intramuscular treatment.
    Kaal A; Orskov H; Nielsen S; Pedroncelli AM; Lancranjan I; Marbach P; Weeke J
    Eur J Endocrinol; 2000 Sep; 143(3):353-61. PubMed ID: 11022177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
    Quabbe HJ; Plöckinger U
    J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Long-term treatment of acromegaly with the somatostatin analog octreotide (Sandostatin). On the predictive significance of acute tests].
    Schmidt K; Althoff PH; Harris A; Hofmeister-Wagner W; Schifferdecker E; Schöffling K
    Med Klin (Munich); 1990 Dec; 85(12):700-6. PubMed ID: 2128367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of acromegaly with long acting somatostatin analogue SMS 201-995.
    Horikawa R; Takano K; Hizuka N; Asakawa K; Sukegawa I; Hirose N; Horiba N; Kasono K; Masuda A; Ohba Y
    Endocrinol Jpn; 1988 Oct; 35(5):741-51. PubMed ID: 3220051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety.
    Ho KY; Weissberger AJ; Marbach P; Lazarus L
    Ann Intern Med; 1990 Feb; 112(3):173-81. PubMed ID: 2404445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Octreotide as primary therapy for acromegaly.
    Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study.
    Newman CB; Melmed S; Snyder PJ; Young WF; Boyajy LD; Levy R; Stewart WN; Klibanski A; Molitch ME; Gagel RF
    J Clin Endocrinol Metab; 1995 Sep; 80(9):2768-75. PubMed ID: 7673422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic administration of the somatostatin analogue SMS 201-995 does not lead to endogenous antibody formation.
    Fuessl HS; Domin J; Anderson JV; Bloom SR
    Aliment Pharmacol Ther; 1987 Feb; 1(1):45-50. PubMed ID: 2979211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-dose response study of the somatostatin analogue octreotide in acromegaly.
    van Liessum PA; Pieters GF; Smals AG; Hermus AR; Benraad TJ; Kloppenborg PW
    Acta Endocrinol (Copenh); 1989 Nov; 121(5):714-20. PubMed ID: 2686331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of subcutaneous infusion versus subcutaneous injections of a somatostatin analogue (SMS 201-995) on the diurnal GH profile in acromegaly.
    Timsit J; Chanson P; Larger E; Duet M; Mosse A; Guillausseau PJ; Harris AG; Moulonguet M; Warnet A; Lubetzki J
    Acta Endocrinol (Copenh); 1987 Sep; 116(1):108-12. PubMed ID: 2889306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
    Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
    Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
    J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long term effects of continuous subcutaneous infusion of the somatostatin analog octreotide in the treatment of acromegaly.
    Tauber JP; Babin T; Tauber MT; Vigoni F; Bonafe A; Ducasse M; Harris AG; Bayard F
    J Clin Endocrinol Metab; 1989 May; 68(5):917-24. PubMed ID: 2565913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group.
    Vance ML; Harris AG
    Arch Intern Med; 1991 Aug; 151(8):1573-8. PubMed ID: 1872661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly.
    Plewe G; Beyer J; Krause U; Neufeld M; del Pozo E
    Lancet; 1984 Oct; 2(8406):782-4. PubMed ID: 6148524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effect of octreotide in acromegaly on insulin resistance.
    Breidert M; Pinzer T; Wildbrett J; Bornstein SR; Hanefeld M
    Horm Metab Res; 1995 May; 27(5):226-30. PubMed ID: 7642173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.
    McKeage K; Cheer S; Wagstaff AJ
    Drugs; 2003; 63(22):2473-99. PubMed ID: 14609359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin analogue (SMS 201-995) in resistant acromegaly: a preliminary report.
    Atkinson AB; McKnight JA; McCance DR; Bell PM
    Horm Res; 1990; 33 Suppl 1():7-11; discussion 11-2. PubMed ID: 2358295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.